Support for association of HSPG2 with tardive dyskinesia in Caucasian populations

L. Greenbaum, A. Alkelai, P. Zozulinsky, Y. Kohn, B. Lerer

Research output: Contribution to journalArticlepeer-review


Tardive dyskinesia (TD) is a severe adverse effect of chronic antipsychotic drug treatment. In addition to clinical risk factors, TD susceptibility is influenced by genetic predisposition. Recently, Syu et al. (2010) reported a genome-wide association screening of TD in Japanese schizophrenia patients. The best result was association of single-nucleotide polymorphism (SNP) rs2445142 in the HSPG2 (heparan sulfate proteoglycan 2) gene with TD. In the present study, we report a replication study of the five top Japanese TD-associated SNPs in two Caucasian TD samples. Applying logistic regression and controlling for relevant clinical risk factors, we were able to replicate the association of HSPG2 SNP rs2445142 with TD in a prospective study sample of 179 Americans of European origin by performing a secondary analysis of the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) genome-wide association study data set, and using a perfect proxy surrogate marker (rs878949; P0.039). An association of the G risk allele of HSPG2 SNP rs2445142 with TD was also shown in a sample of Jewish Israeli schizophrenia patients (retrospective, cross-sectional design; P0.03). Although the associations were only nominally significant, the findings provide further support for the possible involvement of HSPG2 in susceptibility to TD.

Original languageEnglish
Pages (from-to)513-520
Number of pages8
JournalPharmacogenomics Journal
Issue number6
StatePublished - Dec 2012
Externally publishedYes


  • HSPG2
  • antipsychotics
  • schizophrenia
  • tardive dyskinesia


Dive into the research topics of 'Support for association of HSPG2 with tardive dyskinesia in Caucasian populations'. Together they form a unique fingerprint.

Cite this